Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence

被引:0
|
作者
Dinh, Phong Phan [1 ,2 ]
Ho, Tri Huynh Quang [3 ]
Pham, Hung Manh [1 ,2 ,6 ]
Nguyen, Hai Hoang [4 ]
Ton, Minh That [5 ]
Tran, Giang Song [1 ]
Vu, Nga Quynh [6 ]
Pham, Hung Nhu
Cao, Son Luong [7 ]
Hoang, Sy Van [8 ,9 ]
机构
[1] Bach Mai Hosp, Vietnam Natl Heart Inst, Hanoi, Vietnam
[2] Hanoi Med Univ, Hanoi, Vietnam
[3] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[4] Nhan Dan Gia Dinh Hosp, Ho Chi Minh City, Vietnam
[5] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[6] Hanoi Heart Hosp, Hanoi, Vietnam
[7] Univ Med Ctr Ho Chi Minh City, Dept Cardiol, Ho Chi Minh City, Vietnam
[8] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[9] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam
关键词
Rivaroxaban; AF; acute kidney injury; renal failure; anticoagulant -related nephropathy; CHRONIC KIDNEY-DISEASE; CLINICAL-TRIALS; OUTCOMES; RISK; ANTICOAGULANTS; WARFARIN; DECLINE; INJURY;
D O I
10.15420/ecr.2024.07
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: AF is a global health concern, with systemic complications including renal dysfunction. This systematic review and meta-analysis compares the effects of rivaroxaban, a Factor Xa inhibitor, and vitamin K antagonists (VKAs) on renal outcomes in AF patients. Methods: The study protocol is registered in PROSPERO (ID: CRD42023462756). We systematically searched the PubMed, Embase and Cochrane Library databases from 1 January 2017 to 30 June 2023 for real-world studies comparing the effects of rivaroxaban and VKAs on renal outcomes in AF patients, including acute kidney injury, a >= 30% decrease in estimated glomerular filtration rate, doubling of serum creatinine and worsening renal function. Subgroup analyses targeted diabetes, pre-existing kidney disease, the elderly (age >= 65 years) and Asian populations. The risk of bias was assessed used the Robins-I tool. HRs and 95% CIs were synthesised through a random-effects model. Two sensitivity analyses were performed, using a fixed-effects model and excluding conference abstracts. Results: We identified 1,666 records. After screening, 14 studies comparing rivaroxaban and VKAs were included. Rivaroxaban exhibited superiority over VKAs in preventing: acute kidney injury (HR 0.68; 95% CI [0.61-0.77]; p<0.00001); a >= 30% decrease in estimated glomerular filtration rate (HR 0.71; 95% CI [0.60-0.84]; p<0.0001); doubling of serum creatinine (HR 0.50; 95% CI [0.36-0.70]; p<0.0001); and worsening renal function (HR 0.56; 95% CI [0.45-0.69]; p<0.00001). Subgroup and sensitivity analyses consistently confirmed rivaroxaban's favourable effects on renal outcomes in diabetes, pre-existing kidney disease, the elderly and Asian populations. Conclusion: Our findings support the preference of rivaroxaban over VKAs for renal outcomes in AF. The findings endorse rivaroxaban as the preferred anticoagulant to mitigate renal complications, offering clinicians valuable insights for tailored strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] ASPIRIN WITH NON-VITAMIN K ANTAGONISTS VERSUS WITH VITAMIN K ANTAGONISTS FOR ATRIAL FIBRILLATION PATIENTS WITH INDICATION FOR ANTIPLATELETS: EVIDENCE FROM A META-ANALYSIS
    Nairooz, Ramez S.
    Almomani, Ahmed
    Sardar, Partha
    Ayoub, Karam
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 878 - 878
  • [32] DIRECT ORAL ANTICOAGULANTS IN ADULTS WITH NONVALVULAR ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF REAL-WORLD EVIDENCE
    Subash, R.
    Lister, S.
    Lewis, C.
    Rabar, S.
    Hale, M. J.
    Kang, A.
    Dickerson, C.
    VALUE IN HEALTH, 2023, 26 (12) : S42 - S42
  • [33] Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
    Vamos, Mate
    Cappato, Riccardo
    Marchlinski, Francis E.
    Natale, Andrea
    Hohnloser, Stefan H.
    EUROPACE, 2016, 18 (12): : 1787 - 1794
  • [34] Novel Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valve Replacement: A Systematic Review and Meta-Analysis
    Memon, Muhammad
    Amin, Emaan
    Siddiqui, Asad Ali
    Eisha, Waqar
    Asma, Faisal
    Khan, Mohammad
    Minhas, Abdul
    CIRCULATION, 2021, 144
  • [35] Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis
    Martinez, B. K.
    Sheth, J.
    Patel, N.
    Baker, W. L.
    Coleman, C. I.
    THROMBOSIS RESEARCH, 2018, 164 : S205 - S205
  • [36] UNINTERRUPTED EDOXABAN VERSUS RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS FOR ABLATION OF ATRIAL FIBRILLATION
    Elbanhawy, Noha
    Ainslie, Mark
    Eltouky, Sherif
    Gall, Rahul Potluri Scott
    Chalil, Shajil
    Abozguia, Khalid
    HEART, 2019, 105 : A32 - A33
  • [37] Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis
    Martinez, Brandon K.
    Sheth, Jit
    Patel, Nishi
    Baker, William L.
    Coleman, Craig I.
    PHARMACOTHERAPY, 2018, 38 (06): : 610 - 618
  • [38] REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCE
    Bowrin, K.
    Briere, J.
    Millier, A.
    Levy, P.
    Clay, E.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S105 - S105
  • [39] Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study
    Marston, X. L.
    Wang, R.
    Yeh, Y-C
    Zimmermann, L.
    Ye, X.
    Gao, X.
    Brueggenjuergen, B.
    Unverdorben, M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 346 : 93 - 99
  • [40] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
    Bowrin, Kevin
    Briere, Jean-Baptiste
    Fauchier, Laurent
    Coleman, Craig
    Millier, Aurelie
    Toumi, Mondher
    Clay, Emilie
    Levy, Pierre
    PLOS ONE, 2020, 15 (01):